Longitudinal data were available for 80.9% of the patients for the responsiveness analysis.
Feasible and functional CRPC models for drug responsiveness analysis and the development of effective therapies targeting the FGF signaling pathway and other pathways in prostate cancer are being actively investigated.
For this responsiveness analysis, missing data was not imputed.
Hence seventy-five patients were available for the responsiveness analysis.
Participant characteristics for the responsiveness analysis are reported in Table 1.
It would therefore have been preferable with an even longer follow-up period for the responsiveness analysis.
Divergent results between CSOM and PVF for the responsiveness analysis and the criterion validity analysis might be explained by the technical features of the CSOM.
We calculated that we needed 50 patients with an acute injury for the responsiveness analysis and expected 20% drop-outs or missing values.
Several cases were excluded from the analysis; the learners who did not fill-in the pre-test and those who failed to answer the post-test were not taken into account for the responsiveness analysis, as well as those learners who did not attend at least three half-day sessions of the EBP course.
